Clinical Study of Endocrine Hormone Combined with Trastuzumab in Maintenance Treatment of HR and HER-2 Positive Advanced Breast Cancer

  • Xulong Zhu Shaanxi Provincial People’s Hospital & Xi’an Jiaotong University
  • Guangshuai Lin Shaanxi Provincial People’s Hospital
  • Xinmiao Liu Shaanxi Provincial People’s Hospital
  • Yangmeng Feng Shaanxi Provincial People’s Hospital
  • Binliang Huo Shaanxi Provincial People’s Hospital
DOI: https://doi.org/10.18686/aem.v11i3.281
Keywords: Endocrine Hormones, Trastuzumab, Hormone Receptors, Human Epidermal Growth Factor Receptor, Advanced Breast Cancer

Abstract

Objective: To analyze the clinical effect of endocrine hormone combined with trastuzumab in maintenance therapy of HR (hormone receptor) and HER-2 (human epidermal growth factor receptor) positive advanced breast cancer. Methods: A total of 80 patients with HR and HER-2 positive advanced breast cancer admitted to our hospital from January 2020 to December 2022 were selected, and the 80 patients were divided into 2 groups by random number table method, the control group (N= 40) The patients in the observation group (N=40) were treated with trastuzumab, and the patients in the observation group (N=40) were treated with endocrine hormones and trastuzumab for maintenance. The therapeutic effects of the two groups were compared. Results: The two groups of patients had similar serum CD8+, CD4+, CD3+ before treatment and CD8+ after treatment (P>0.05). After treatment, the CD4+ and CD3+ in the observation group were higher than those in the control group (P<0.05). The total effective rate of the observation group was significantly higher than that of the control group. It was higher in the control group (P<0.05); the incidence of adverse reactions in the observation group was lower than that in the control group (P<0.05). Conclusion: Endocrine hormone combined with trastuzumab maintenance therapy for HR and HER-2 positive advanced breast cancer has significant clinical effect, can effectively improve the immune indexes of patients, and has less adverse reactions, which is worthy of clinical application.

References

[1] Song ZJ. Effect of Trastuzumab Combined with Tamoxifen in the Treatment of Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Positive Advanced Breast Cancer [J]. Chinese Journal of Primary Medicine, 2018,25(11):1424-1427.

[2] Huang L, Wang DF, Li HL, et al. Survival Analysis of Everolimus Combined with Endocrine Therapy in Patients with Advanced Hormone Receptor-positive HER-2 negative Breast Cancer [J]. Chinese Journal of Gerontology, 2019, 39(8):1833-1836.

[3] Shen CY, Jin XX, Wang SL. Effects of Trastuzumab Combined with GEM and CAP Chemotherapy on Serum T cell Subsets, TPS Levels and Quality of Life in Patients with HER-2 Positive Advanced Breast Cancer [J]. China Medical Review,2019,16(19):93-97.

[4] Yun ZH, Li HP. Research Progress of Multi-targeted Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2 Positive Advanced Breast Cancer [J]. Cancer Progression, 2021,19(18):1852-1857,1867.

[5] Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Drug Clinical Research Committee of Chinese Anti-Cancer Association. Clinical Application of CDK4/6 Inhibitor in the Treatment of Hormone Receptor-positive Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer [J]. Chinese Journal of Oncology, 2021,43(4):405-413.

[6] Chang W, Ding M, Zhou JH, et al. Efficacy and Safety of Trastuzumab Combined with Paclitaxel in the Treatment of Human Epidermal Growth Factor Receptor-2 Overexpressing Metastatic Breast Cancer [J]. Journal of Xinxiang Medical College, 2018, 35(6): 517-520.
Published
2022-11-04
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Xulong Zhu

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.